

chronic heart failure, wherein the method comprises administering a compressed solid dosage form as defined in claim <sup>18</sup>33 to a subject in need of such treatment.

<sup>18</sup>45. A method of treating according to claim <sup>17</sup>44 wherein the compressed solid dosage form is orally administered to the subject.

<sup>9</sup>46. A method of treating hypertension, congestive heart failure, angina, myocardial infarction, arteriosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, stroke, left ventricular hypertrophy, cognitive dysfunction, headache, or chronic heart failure, wherein the method comprises administering a compressed solid dosage form as defined in claim <sup>11</sup>38 to a subject in need of such treatment.

<sup>20</sup>47. A method of treating according to claim <sup>19</sup>46 wherein the compressed solid dosage form is orally administered to the subject.

<sup>21</sup>48. A method of treating hypertension, congestive heart failure, angina, myocardial infarction, arteriosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, stroke, left ventricular hypertrophy, cognitive dysfunction, headache, or chronic heart failure, wherein the method comprises administering a compressed solid dosage form as defined in claim <sup>13</sup>40 to a subject in need of such treatment.

<sup>20</sup>49. A method of treating according to claim <sup>21</sup>48 wherein the compressed solid dosage form is orally administered to the subject.

#### REMARKS

Examination of this application and early allowance are respectfully requested.

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6807

Diane Tso  
Diane Tso  
Attorney for Applicants  
Reg. No. 46,012

Date: August 13, 2001